Paromomycin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Aminoglycoside antibiotic from Streptomyces rimosus forma paromycinus.

IndicationThis section has been translated automatically.

  • Systemic: Infections with gram-positive germs, E. coli, Enterobacter, Klebsiellen, Salmonella, Shigella, Proteus.
  • Topical: Leishmaniasis, cutaneous.

Dosage and method of useThis section has been translated automatically.

  • Systemic: 25-30 mg/kg bw/day p.o. in 3 ED over 5-10 days.
  • Topical: Apply 10-20% in ointments or creams 1-2 times/day under occlusion to the affected skin areas.

Undesirable effectsThis section has been translated automatically.

Oto- and nephrotoxicity.

PreparationsThis section has been translated automatically.

Humatin; Leshcutan (available through the international pharmacy, registered in Israel)

Note(s)This section has been translated automatically.

Remember! In ointment form effective against cutaneous leishmaniasis.

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer